Last reviewed · How we verify
GW274150
GW274150 is a selective, non-peptide, orally active, small molecule antagonist of the human corticotropin-releasing factor receptor type 1 (CRF1R).
GW274150 is a selective, non-peptide, orally active, small molecule antagonist of the human corticotropin-releasing factor receptor type 1 (CRF1R). Used for Treatment-resistant depression.
At a glance
| Generic name | GW274150 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | CRF1 receptor antagonist |
| Target | CRF1R |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
GW274150 acts by blocking the action of corticotropin-releasing factor (CRF), a hormone involved in the body's stress response. This leads to a decrease in the production of stress hormones such as cortisol and adrenocorticotropic hormone (ACTH).
Approved indications
- Treatment-resistant depression
Common side effects
- Nausea
- Headache
- Fatigue
- Dizziness
Key clinical trials
- Study With GW274150 In Patients With Mild Asthma (PHASE1)
- Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA) (PHASE2)
- Use Of GW274150 In The Prophylactic Treatment Of Migraine (PHASE2)
- A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days. (PHASE2)
- An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |